GMAB
Genmab A/S
NASDAQ · Healthcare · Biotechnology · DK
$33.60
−2.35%Year over year
Reported trailing growth
- Revenue
- -68.2%
- EBITDA
- -75.8%
- EBIT
- -71.3%
- EPS
- -85.0%
- Free cash flow
- -66.6%
- Operating cash flow
- -67.1%
Forward estimates
Based on analyst estimates
- Revenue
- +16.1%
- EBITDA
- +20.3%
- EPS
- +1.7%
Three-year CAGR
- Revenue
- -36.4%
- EBITDA
- -43.3%
- EBIT
- -41.6%
- Net income
- -43.9%
- EPS
- -42.9%
- Free cash flow
- -31.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026